TREM2 as a Potential Immune-Related Biomarker of Prognosis in Patients with Skin Cutaneous Melanoma Microenvironment

Table 3

OS and clinical characteristic association by Cox regression analyses.

Characteristics	Univariate analysis		Multivariate analysis
	Hazard ratio (95%, CI)	value	Hazard ratio (95%, CI)	value
Gender/sex
Female	Reference
Male	1.164 (0.872-1.554)	0.301
Age
≤60	Reference
>60	1.678 (1.266-2.225)	<0.001	1.292 (0.915-1.825)	0.146
BMI
≤25	Reference
>25	0.819 (0.508-1.321)	0.414
Tumor tissue site
Extremities	Reference
Trunk	0.943 (0.694-1.281)	0.707
Head and neck	1.222 (0.718-2.082)	0.460
Other specify	2.109 (1.095-4.062)	0.026
T-stage
T1	Reference
T2	1.519 (0.824-2.800)	0.180	2.018 (1.014-4.017)	0.046
T3	2.069 (1.141-3.752)	0.017	3.391 (1.396-8.237)	0.007
T4	3.673 (2.047-6.591)	<0.001	6.640 (2.752-16.021)	<0.001
N stage
N0	Reference
N1	1.487 (1.007-2.197)	0.046	2.677 (0.907-7.906)	0.075
N2	1.525 (0.967-2.406)	0.069	2.786 (0.918-8.452)	0.070
N3	2.578 (1.651-4.028)	<0.001	6.361 (2.085-19.413)	0.001
M stage
M0	Reference
M1	1.734 (0.915-3.287)	0.092	0.608 (0.142-2.598)	0.502
Radiation therapy
No	Reference
Yes	0.953 (0.674-1.348)	0.785
Pathologic stage
Stage I	Reference
Stage II	1.566 (1.041-2.356)	0.031	0.603 (0.288-1.261)	0.179
Stage III	1.943 (1.315-2.871)	<0.001	0.374 (0.112-1.246)	0.109
Stage IV	3.174 (1.567-6.428)	0.001
Race
Asian	Reference
Black or African American	NA (NA-NA)
White	0.223 (0.103-0.483)	<0.001	0.265 (0.101-0.695)	0.007
TREM2
Low	Reference
High	0.734 (0.561-0.961)	0.024	0.635 (0.459-0.879)	0.006